Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 days
Summary
This trial is testing a new drug called BMS-986308 to see if it is safe and how it affects healthy people. Researchers want to know how the drug behaves in the body and if it causes any side effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 72 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
Other study objectives
Incidence of Adverse Events (AEs)
Incidence of adverse events (AEs) leading to discontinuation
Incidence of clinically significant changes in cardiac telemetry
+11 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Part B (SAD)Experimental Treatment2 Interventions
Single Ascending Dose (SAD)
Group II: Part A FurosemideExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986308
2021
Completed Phase 1
~50
Furosemide
2015
Completed Phase 4
~4240
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,688 Previous Clinical Trials
4,096,761 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger